Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

• Main Authors: Diane M. Thiboutot (Author), Noah Craft (Author), Robert Rissmann (Author), Ewa Gatlik (Author), Malika Souquières (Author), Julie Jones (Author), Christian Loesche (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background CJM112 is a potent anti-IL-17A monoclonal antibody, whose clinical efficacy in psoriasis was recently documented. This study aimed to assess the effect of IL-17A blockade, using CJM112, in patients with moderate to severe acne. Methods A randomized, placebo-controlled, double-blind, paral...